vs
Side-by-side financial comparison of Dime Community Bancshares, Inc. (DCOM) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $123.8M, roughly 1.4× Dime Community Bancshares, Inc.). On growth, Dime Community Bancshares, Inc. posted the faster year-over-year revenue change (3040.1% vs 143.7%). Over the past eight quarters, Dime Community Bancshares, Inc.'s revenue compounded faster (22.9% CAGR vs 10.6%).
The Dime Community Bank, originally known as the Dime Savings Bank of Williamsburgh, is a local, FDIC-insured bank headquartered in Hauppauge, New York. Founded in 1864, the bank was originally based in the Williamsburg neighborhood of Brooklyn, New York, and continues to operate with a strong market presence in this area. In 2017, Dime moved its headquarters to Brooklyn Heights. On Monday, February 1, 2021, Bridge Bancorp Inc. and Dime Community Bancshares successfully closed on a merger of ...
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DCOM vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $168.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 38.6% | 50.6% |
| Net Margin | — | — |
| Revenue YoY | 3040.1% | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.68 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $168.4M | ||
| Q3 25 | $115.6M | $87.3M | ||
| Q2 25 | $109.7M | $82.4M | ||
| Q1 25 | $103.8M | $65.0M | ||
| Q4 24 | $3.9M | $69.1M | ||
| Q3 24 | $87.6M | $51.6M | ||
| Q2 24 | $87.3M | $73.8M | ||
| Q1 24 | $82.0M | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | $27.7M | $-31.3M | ||
| Q2 25 | $29.7M | $-12.7M | ||
| Q1 25 | $21.5M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.3M | $-29.5M | ||
| Q2 24 | $18.5M | $-61.9M | ||
| Q1 24 | $17.7M | $61.0M |
| Q4 25 | 38.6% | 50.6% | ||
| Q3 25 | 34.7% | -11.4% | ||
| Q2 25 | 36.6% | 8.6% | ||
| Q1 25 | 27.6% | -34.0% | ||
| Q4 24 | -433.6% | -6.4% | ||
| Q3 24 | 20.8% | -31.0% | ||
| Q2 24 | 29.8% | 3.5% | ||
| Q1 24 | 29.6% | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | 23.9% | -35.9% | ||
| Q2 25 | 27.1% | -15.4% | ||
| Q1 25 | 20.7% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 15.2% | -57.2% | ||
| Q2 24 | 21.2% | -83.9% | ||
| Q1 24 | 21.6% | 44.3% |
| Q4 25 | $0.68 | $0.32 | ||
| Q3 25 | $0.59 | $-0.16 | ||
| Q2 25 | $0.64 | $-0.06 | ||
| Q1 25 | $0.45 | $-0.21 | ||
| Q4 24 | $-0.58 | $-0.14 | ||
| Q3 24 | $0.29 | $-0.15 | ||
| Q2 24 | $0.43 | $-0.33 | ||
| Q1 24 | $0.41 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $-302.0M |
| Total Assets | $15.3B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $1.5B | $-302.0M | ||
| Q3 25 | $1.5B | $-451.4M | ||
| Q2 25 | $1.4B | $-433.5M | ||
| Q1 25 | $1.4B | $-426.2M | ||
| Q4 24 | $1.4B | $-388.7M | ||
| Q3 24 | $1.3B | $-370.2M | ||
| Q2 24 | $1.3B | $-344.2M | ||
| Q1 24 | $1.2B | $-294.3M |
| Q4 25 | $15.3B | $465.9M | ||
| Q3 25 | $14.5B | $364.0M | ||
| Q2 25 | $14.2B | $347.1M | ||
| Q1 25 | $14.1B | $324.0M | ||
| Q4 24 | $14.4B | $343.8M | ||
| Q3 24 | $13.7B | $314.1M | ||
| Q2 24 | $13.5B | $352.3M | ||
| Q1 24 | $13.5B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $186.6M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $186.6M | $45.2M | ||
| Q3 25 | $52.1M | $-4.3M | ||
| Q2 25 | $23.1M | $-31.4M | ||
| Q1 25 | $65.4M | $-22.6M | ||
| Q4 24 | $99.1M | $-35.0M | ||
| Q3 24 | $-33.3M | $-35.3M | ||
| Q2 24 | $12.6M | $-7.2M | ||
| Q1 24 | $30.7M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | $51.2M | — | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-34.1M | $-35.5M | ||
| Q2 24 | $9.2M | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | 44.3% | — | ||
| Q2 25 | 18.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -38.9% | -68.7% | ||
| Q2 24 | 10.5% | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.7% | 0.0% | ||
| Q2 25 | 2.4% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 0.9% | 0.3% | ||
| Q2 24 | 3.9% | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.88× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 3.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.50× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 1.74× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DCOM
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
